Agilux Laboratories Hires New Senior Director to Lead Pharmacology Operations

WORCESTER, Mass.--(BUSINESS WIRE)--Agilux Laboratories, a leading provider of Drug Metabolism and Pharmacokinetics (DMPK) services to pharmaceutical and biotechnology firms, is pleased to announce that Geeta Sharma, Ph.D. has joined the Agilux team as Senior Director, Pharmacology. In this role, Dr. Sharma will lead the Pharmacology group and will initially be focused on developing and launching non-GLP discovery oncology services. Dr. Sharma will also serve as a member of the senior management team.

Dr. Sharma has more than 15 years of experience in Drug Discovery in multiple therapeutic areas including oncology, infectious diseases, metabolic disorders, and inflammation. She has led discovery programs that have successfully translated to clinical candidates. She has published more than 15 research articles and has contributed to 11 patents. Most recently, Dr. Sharma was Senior Director, Pharmacology at Forma Therapeutics (Massachusetts-based company) at their Singapore location. Prior to this, Dr. Sharma has held roles of increasing responsibility at Combinatorx Singapore and Ranbaxy Laboratories, LTD.

"We are very pleased to have Dr. Sharma join our team here at Agilux," said Jim Jersey, President and CEO. "Dr. Sharma brings to us extensive knowledge and industry experience in discovery pharmacology and we look forward to her contributions and guidance in adding oncology pharmacology services to complement our continually expanding portfolio of discovery services. Given the industry's increasing focus on oncology therapeutic discovery and development within R&D, we are excited to offer these new services to our clients."

Dr. Sharma added, "I am excited to be an integral part of the team here at Agilux at a time when the discovery efforts in oncology are reaching their peak in the pharmaceutical industry. I look forward to leveraging Agilux's excellent infrastructure, systems and client rapport to set up and establish new capabilities that can help the industry expedite their discovery programs."

About Agilux Laboratories Inc.

Agilux Laboratories Inc., with over 90 employees and greater than 50,000 square feet of facility space, is a leading New England-based contract research organization (CRO) that has developed into one of the fastest growing CRO's in the Boston/Cambridge biotech arena. Agilux Labs is driven by its ability to offer "Better Data Faster" across a broad range of services supporting drug discovery, pre-clinical and clinical services. Our full range of Drug Metabolism and Pharmacokinetic services, include fit-for-purpose rapid turnaround LC-MS/MS Bioanalysis, In-Vivo PK, and In-Vitro Assay services. With corresponding clinical site support, GLP LC-MS/MS Bioanalytical services are also provided to support regulated pre-clinical and clinical studies. To learn more, please visit us atwww.agiluxlabs.com.

Contacts

Steve Guyan, 508-753-5000
MS, Vice President, Sales and Marketing
[email protected]
Fax: 508-630-1679

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.